Novartis Announces FDA Approval Of Egaten - Quick Facts

(RTTNews) - Novartis (NVS) announced the US FDA has approved Egaten (triclabendazole) for the treatment of fascioliasis in patients six years of age and older. The company said this makes Egaten the only FDA-approved drug for people with the disease.

Novartis has been donating Egaten to the WHO since 2005. It is supplied by WHO during epidemic outbreaks and for periodic use in endemic countries. Novartis said the FDA approval of Egaten is expected to facilitate drug licensing and import to these countries, helping ensure sufficient and prompt availability of the drug when needed.